• NEWS . 11 Jan 2021
  • Increased serum serotonin in ACS patients undergoing PCI may warrant more effective treatment

  • It is known that activated platelets release serotonin, which can cause platelet aggregation and vasoconstriction. Considering this, researchers in Korea conducted a study to investigate serotonin levels in patients with acute coronary syndrome (ACS) and chronic stable angina (CSA) treated with percutaneous coronary intervention (PCI).

    Participants of the study were consecutive patients undergoing PCI for either ACS or CSA enrolled between July 2009 and April 2010 and who were pretreated with dual antiplatelet agents before the procedure. Serum serotonin levels, measured at baseline, pre- and post-PCI, and at 90 minutes and 6, 12, 24 and 48 hours after PCI, were compared between the ACS and CSA groups.

    A total of 63 ACS patients and 60 CSA patients were included, with similar overall baseline characteristics between both groups. The ACS group was observed to have significantly higher serotonin levels at post-PCI as well as at peak compared with the CSA group. However, at 90 minutes and 6, 24 and 48 hours post-PCI serum serotonin was numerically, but not significantly, higher in patients with ACS. Serotonin levels fluctuated in both groups, showing an initial rise and fall, rebound at 24 hours, and drop at 48 hours post-PCI.

    The study concluded that in patients undergoing PCI, serum serotonin was more elevated in patients with ACS than in those with CSA, which may imply the need for more potent and sustained platelet inhibition, particularly in patients with ACS.

    Reference:
    Han D, et al. Changes in serum serotonin levels in patients with acute coronary syndrome and stable angina undergoing percutaneous coronary intervention. J Int Med Res 2020;48:300060520970104.